New online! Optimizing CAR T cell therapy for solid tumours: a clinical perspective nature.com/articles/s4157…

Outcome of pts w Mantle Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy is partic poor: Descar-T Study ⁦Lysa Lymphoma⁩ Bispec Abs appear promising offering durable responses c.f to chemotherapy & targeted therapy ⁦Blood Advances⁩ ashpublications.org/bloodadvances/…

Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe ⁦Blood Advances⁩ ⁦MarieJosé Kersten⁩ ashpublications.org/bloodadvances/…

Best #Heme team ever. What a wonderful celebration of our hematology teams in our annual heme team appreciation day. Yale Cancer Center Yale University Yale School of Medicine YaleHematology

Germline CHEK2 variants are identified in 2.2% of cases with early-onset and familial myeloproliferative neoplasms #MPN doi.org/10.1002/ajh.70…

Low-dose Nivolumab and Lenalidomide in Relapsed/Refractory Hodgkin Lym... sciencedirect.com/science/articl…. Vikram Mathews Uday Kulkarni Phaneendra Datari

Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for BBB penetration Pola exhibits sign pre-clinical activity V’s PCNSL & SCNSL xenografts & partially penetrates BBB in CNS lymphoma patients w CSF drug conc reaching 0.56% - 1.31% plasma levels ashpublications.org/bloodadvances/…

Novel chemotherapy-free combinations further amplify glofitamab activity and present promising tailored alternatives to SOC treatments. Read the full article in Blood: ow.ly/kFG350X9rgM

FDA new drug approvals in Q3 2025 nature.com/articles/d4157… Q3 saw a welcome bolus of novel FDA drug approvals, with the 16 approvals matching the 16 approvals in total in the first half of the year, including the first drug for bronchiectasis nature.com/articles/d4157…

Microenvironmental regulation of solid tumour resistance to CAR T cell therapy bit.ly/47bokGU

#Hematology Point-of-care #CARTcell therapy: toward broader access #lymsm ashpublications.org/bloodadvances/…

Patient- vs clinician-reported AEs from POLARIX Carrie Thompson, MD: - symptom incidence & severity much higher as assessed by PROs - sustained improvements in all QOL domains except cog functioning (worse in R-CHOP arm) We must measure PROs in #lymsm trials! ashpublications.org/blood/article/…

Look out for important data here coming soon #MCL #sonrotoclax #lymsm

For readers interested in cancer therapies, this Review in the October issue discusses how metabolic modulators and dietary nutrients can improve the anticancer immune response and overcome drug resistance mechanisms rdcu.be/eLS8A nature.com/articles/s4157…

Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial | Journal of Clinical Oncology ascopubs.org/doi/pdf/10.120…

Researchers from Google and Yale have created a powerful new #AI model that analyzes single-cell #RNA data. Built on large language models, it could help unlock big biological discoveries—including a promising new path for #cancer treatment. yalecancercenter.org/news-article/b… Smilow Cancer Hospital

Nice study of risk-adapted treatment in mantle cell lymphoma, adding 2 years of venetoclax to RBAC in older patients with high(er) risk MCL In the higher-risk group, 2-yr PFS 60%, median PFS 37 months thelancet.com/journals/lanha… #lymsm The Lancet Haematology

Polatuzumab vedotin and CD79B: A study of efficacy in R-CHOP-resistant diffuse large B-cell lymphoma buff.ly/XhH4oqT

Intrinsically disordered proteins are dysregulated in disease, but have been considered 'undruggable'. This Review in the October issue discusses experimental and computational approaches to conquer this barrier in drug discovery rdcu.be/eMbXh nature.com/articles/s4157…

2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia buff.ly/4Uy1kFv